RecruitingNot ApplicableNCT04429594

Study of the Incidence of SARS-CoV-2 Infection (COVID-19)

Study of the Incidence of SARS-CoV-2 Infection in the Alpes-Maritimes Department by Analysis of the Specific Humoral and Cellular Response During Deconfinement

Sponsor

Centre Hospitalier Universitaire de Nice

Enrollment

1,000 participants

Start Date

Jul 28, 2020

Study Type

INTERVENTIONAL

Conditions

Coronavirus Infections

Summary

This is a prospective observational cohort study that will define the prevalence and incidence of CA-SARS-Cov2 infection using serological and PCR tests in a group of subjects during deconfinement. The team wishes to include approximately 1000 subjects in this study. The health crisis through containment has also created unprecedented environmental conditions with the very clear decrease in economic activities and a consequent decrease in exposure to the main air pollutants. The aim is therefore to carry out a case-control study in which each subject will be his or her own control in unexposed condition (to PM2.5, PM10, NO...) then exposed (after the recovery of economic activity and the usual levels of air pollutants) and to measure the impact of these pollutants on the immune system and epigenetic markers taking into account seasonality. The occurrence of infectious, cardiovascular, allergic and autoimmune events will then be measured according to the immunological profiles measured at inclusion.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This study is tracking how many people in a specific region of France (Department 06) got infected with SARS-CoV-2 (the virus that causes COVID-19). It started in May 2020, shortly after the first lockdown ended, and aimed to understand how widely the virus was spreading in the general community — especially among people who are regularly exposed to the public, like workers in retail, transport, or social services. By following participants over time with regular testing and questionnaires, researchers could estimate true infection rates, including people who had mild or no symptoms and never got tested. This kind of data helps public health officials understand who is most at risk and how effective containment measures are. You may be eligible if: - You are 18 years old or older - You were exposed to the public from May 11, 2020 onward - You were informed about the study through partner institutions (e.g., Departmental Council 06) - You are affiliated with a French social security scheme You may NOT be eligible if: - You are legally protected under tutorship or guardianship - You are unable to participate in a clinical study under French Public Health Code Article L.1121-16 Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.